Abstract:Background Melatonin (MEL) is an indole amine molecule primarily produced in the pineal gland. Melatonin has been shown in numerous studies to have antifibrotic effects on the kidney, liver, and other organs. However, it is still unclear how melatonin works in bladder fibrosis. We explored how melatonin affects animals with bladder fibrosis and the underlying mechanisms. Materials and methods MEL was used to treat human bladder smooth muscle cells (HBdSMCs) after they were stimulated with transforming growth factor-β1 (TGF-β1) in vitro . Proteomic analysis and bioinformatic analysis of the altered expression of these proteins were subsequently performed on HBdSMCs from the different processing methods. To construct an in vivo bladder fibrosis model, we injected protamine sulfate (PS) and lipopolysaccharide (LPS) twice a week into the rat bladder for six weeks. After two weeks of PS/LPS treatment, the mice in the treatment group were treated with MEL (20 mg/kg/d) for 4 weeks. Finally, we detected the expression of fibrosis markers from different perspectives. The TGF-β1/Smad pathway and epithelial–mesenchymal transition (EMT) in cell and bladder tissues were also identified. Further proteomic analysis was also performed. Results In vitro , we found that TGF-β1 treatment enhanced the expression of the fibrosis markers collagen III and α-SMA in HBdSMCs. E-cadherin expression decreased while the TGF-β1/Smad pathway was activated. Vimentin and N-cadherin expression was also elevated at the same time. Similar findings were observed in the LPS group. After MEL treatment, the expression of collagen III and α-SMA decreased, the expression of E-cadherin increased, and the expression of vimentin and N-cadherin also decreased. According to our quantitative proteomics analysis, CCN1 and SQLE may be important proteins involved in the development of bladder fibrosis. MEL decreased the expression of these genes, leading to the relief of bladder fibrosis. Bioinformatics analysis revealed that the extracellular space structure related to metabolic pathways, actin filament binding, and stress fibers can serve as a pivotal focus in the management of fibrosis. Conclusion Melatonin attenuates bladder fibrosis by blocking the TGF-β1/Smad pathway and EMT. CCN1 appears to be a possible therapeutic target for bladder fibrosis.

Melatonin ameliorates hepatic fibrosis via the melatonin receptor 2-mediated upregulation of BMAL1 and anti-oxidative enzymes

Protective Role of Melatonin in Early‐stage and End‐stage Liver Cirrhosis

Beneficial effects of melatonin on liver fibrosis: A systematic review of current biological evidence

Preventive and therapeutic effects of melatonin on rat fatty liver induced by high fat feeding

Inhibition of the SphK1/S1P signaling pathway by melatonin in mice with liver fibrosis and human hepatic stellate cells

Melatonin Prevents Thioacetamide–Induced Gut Leakiness and Liver Fibrosis Through the Gut–Liver Axis via Modulating Sirt1‐Related Deacetylation of Gut Junctional Complex and Hepatic Proteins

Melatonin Alleviates Diet-Induced Steatohepatitis by Targeting Multiple Cell Types in the Liver to Suppress Inflammation and Fibrosis.

Inflammation‐Responsive Cell Membrane‐Camouflaged Nanoparticles against Liver Fibrosis via Regulating Endoplasmic Reticulum Stress and Oxidative Stress

Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR‐141‐mediated NLRP3 inflammasome and TGF‐β1/Smads signaling in diabetic cardiomyopathy

Melatonin prevents pulmonary fibrosis caused by PM2.5 exposure by targeting epithelial-mesenchymal transition

Effect of melatonin on oxidative stress indicators in animal models of fibrosis: A systematic review and meta-analysis

Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice

Melatonin prevents lung injury induced by hepatic ischemia–reperfusion through anti-inflammatory and anti-apoptosis effects

Melatonin improves cholestatic liver disease via the gut-liver axis

Melatonin Safeguards Against Fatty Liver by Antagonizing TRAFs‐mediated ASK1 Deubiquitination and Stabilization in a Β‐arrestin‐1 Dependent Manner

A Research on the Mechanism of Melatonin Against Rat Liver Fibrosis

Melatonin: a Potential Intervention for Hepatic Steatosis

Melatonin serves as a novel treatment in bladder fibrosis through TGF-β1/Smad and EMT

Melatonin Upregulates the Activity of AMPK and Attenuates Lipid Accumulation in Alcohol-induced Rats.

Hepatoprotective actions of melatonin: Possible mediation by melatonin receptors

Melatonin Inhibits Fibroblast Cell Functions and Hypertrophic Scar Formation by Enhancing Autophagy Through the MT2 Receptor-Inhibited PI3K/Akt /mtor Signaling.